UBS Maintains Neutral on Aflac, Raises Price Target to $125
UBS analyst Michael Ward maintains Aflac (NYSE:AFL) with a Neutral and raises the price target from $124 to $125.
Stocks · News reference
Wolfe Research Initiates Coverage On Aflac with Underperform Rating, Announces Price Target of $103
Wolfe Research analyst Tracy Benguigui initiates coverage on Aflac (NYSE:AFL) with a Underperform rating and announces Price Target of $103.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Can MetLife's Group Benefits Segment Maintain Its Momentum?
MetLife's Group Benefits segment reported 25% year-over-year earnings growth in Q2 2026, driven by volume growth and improved underwriting. Group Life's mortality ratio improved to 79%, below the 83%-88% target range. However, some mortality benefits may not persist as about 2 percentage points reflected prior-period development. Competitors The Hartford and Aflac showed mixed results, with Hartford's employee benefits expanding but facing higher disability loss ratios, while Aflac's earnings declined despite sales growth.
Jim Cramer Recommends Buying This Communication Services Stock, Calling It ‘Amazing’
Cramer backs Sphere and Cameco, urges selling AppLovin, criticizes Honeywell and QXO, and sees limited-risk upside in Aflac.